Aegerion Pharma (AEGR) Misses Q2 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results
August 9, 2016 4:11 PM EDT-- Company records $44.5 million in total net product sales ---- Company reiterates 2016 total net product sales guidance of between $130 and $150 million --
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Â Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business update for the second quarter of 2016.
Highlights
Aegerion recorded total... More